Cargando…
Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial
BACKGROUND: Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pain modulation and perception, including occipital areas. However, whether these...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605508/ https://www.ncbi.nlm.nih.gov/pubmed/34800989 http://dx.doi.org/10.1186/s10194-021-01347-y |
_version_ | 1784602194750734336 |
---|---|
author | Schading, Simon Pohl, Heiko Gantenbein, Andreas Luechinger, Roger Sandor, Peter Riederer, Franz Freund, Patrick Michels, Lars |
author_facet | Schading, Simon Pohl, Heiko Gantenbein, Andreas Luechinger, Roger Sandor, Peter Riederer, Franz Freund, Patrick Michels, Lars |
author_sort | Schading, Simon |
collection | PubMed |
description | BACKGROUND: Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pain modulation and perception, including occipital areas. However, whether these structural alterations can be dynamically modulated through tDCS treatment is understudied. OBJECTIVE: To track longitudinally grey matter volume changes in occipital areas in episodic migraineurs during and up to five months after occipital tDCS treatment in a single-blind, and sham-controlled study. METHODS: 24 episodic migraineurs were randomized to either receive verum or sham occipital tDCS treatment for 28 days. To investigate dynamic grey matter volume changes patients underwent structural MRI at baseline (prior to treatment), 1.5 months and 5.5 months (after completion of treatment). 31 healthy controls were scanned with the same MRI protocol. Morphometry measures assessed rate of changes over time and between groups by means of tensor-based morphometry. RESULTS: Before treatment, migraineurs reported 5.6 monthly migraine days on average. A cross-sectional analysis revealed grey matter volume increases in the left lingual gyrus in migraineurs compared to controls. Four weeks of tDCS application led to a reduction of 1.9 migraine days/month and was paralleled by grey matter volume decreases in the left lingual gyrus in the treatment group; its extent overlapping with that seen at baseline. CONCLUSION: This study shows that migraineurs have increased grey matter volume in the lingual gyrus, which can be modified by tDCS. Tracking structural plasticity in migraineurs provides a potential neuroimaging biomarker for treatment monitoring. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03237754. Registered 03 August 2017 – retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03237754. |
format | Online Article Text |
id | pubmed-8605508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-86055082021-11-22 Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial Schading, Simon Pohl, Heiko Gantenbein, Andreas Luechinger, Roger Sandor, Peter Riederer, Franz Freund, Patrick Michels, Lars J Headache Pain Research Article BACKGROUND: Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pain modulation and perception, including occipital areas. However, whether these structural alterations can be dynamically modulated through tDCS treatment is understudied. OBJECTIVE: To track longitudinally grey matter volume changes in occipital areas in episodic migraineurs during and up to five months after occipital tDCS treatment in a single-blind, and sham-controlled study. METHODS: 24 episodic migraineurs were randomized to either receive verum or sham occipital tDCS treatment for 28 days. To investigate dynamic grey matter volume changes patients underwent structural MRI at baseline (prior to treatment), 1.5 months and 5.5 months (after completion of treatment). 31 healthy controls were scanned with the same MRI protocol. Morphometry measures assessed rate of changes over time and between groups by means of tensor-based morphometry. RESULTS: Before treatment, migraineurs reported 5.6 monthly migraine days on average. A cross-sectional analysis revealed grey matter volume increases in the left lingual gyrus in migraineurs compared to controls. Four weeks of tDCS application led to a reduction of 1.9 migraine days/month and was paralleled by grey matter volume decreases in the left lingual gyrus in the treatment group; its extent overlapping with that seen at baseline. CONCLUSION: This study shows that migraineurs have increased grey matter volume in the lingual gyrus, which can be modified by tDCS. Tracking structural plasticity in migraineurs provides a potential neuroimaging biomarker for treatment monitoring. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03237754. Registered 03 August 2017 – retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03237754. Springer Milan 2021-11-20 /pmc/articles/PMC8605508/ /pubmed/34800989 http://dx.doi.org/10.1186/s10194-021-01347-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Schading, Simon Pohl, Heiko Gantenbein, Andreas Luechinger, Roger Sandor, Peter Riederer, Franz Freund, Patrick Michels, Lars Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title | Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title_full | Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title_fullStr | Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title_full_unstemmed | Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title_short | Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial |
title_sort | tracking tdcs induced grey matter changes in episodic migraine: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605508/ https://www.ncbi.nlm.nih.gov/pubmed/34800989 http://dx.doi.org/10.1186/s10194-021-01347-y |
work_keys_str_mv | AT schadingsimon trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT pohlheiko trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT gantenbeinandreas trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT luechingerroger trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT sandorpeter trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT riedererfranz trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT freundpatrick trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial AT michelslars trackingtdcsinducedgreymatterchangesinepisodicmigrainearandomizedcontrolledtrial |